Clobetasol Propionate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Corticosteroid-responsive dermatoses (inflammatory and pruritic manifestations) | ≥12 years (cream/ointment/gel/solution) | Short-term topical monotherapy | FDA Approved |
| Moderate to severe plaque-type psoriasis | ≥16 years (emollient cream); ≥18 years (spray/lotion) | Short-term topical monotherapy | FDA Approved |
| Moderate to severe atopic dermatitis (short-term relief) | ≥12 years | Short-term topical monotherapy | FDA Approved |
| Scalp dermatoses (psoriasis, seborrheic dermatitis of scalp) | ≥12 years (solution); ≥18 years (shampoo) | Short-term topical monotherapy | FDA Approved |
Clobetasol propionate is the most potent topical corticosteroid available, classified as super-high potency (US Class I / WHO Group IV). It is indicated for short-term treatment of moderate to severe inflammatory dermatoses that have not responded to less potent agents. Due to its potency and risk of hypothalamic-pituitary-adrenal (HPA) axis suppression, clobetasol propionate is intended as a second-line or rescue therapy, not a first-choice topical steroid. Treatment should be limited to the minimum duration necessary to achieve control, generally no more than 2 consecutive weeks for most formulations.
Vulvar lichen sclerosus — Evidence quality: High. Clobetasol propionate 0.05% ointment is considered first-line therapy for vulvar lichen sclerosus per multiple international guidelines, though the specific formulation is not separately FDA-approved for this indication.
Alopecia areata — Evidence quality: Moderate. Used as initial topical therapy for limited patchy alopecia areata to induce regrowth.
Oral lichen planus — Evidence quality: Moderate. Topical clobetasol in an adhesive paste vehicle is commonly used for symptomatic erosive oral lichen planus.
Vitiligo (adjunctive) — Evidence quality: Low-Moderate. Used off-label to repigment limited vitiligo patches, particularly on the face and neck.
Cutaneous graft-versus-host disease — Evidence quality: Moderate. First-line topical therapy for acute and chronic cutaneous GVHD.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe plaque psoriasis — localized (≤20% BSA) | Thin film BID to affected areas | Thin film BID | 50 g/week; max 2–4 weeks | Step down to lower-potency steroid once control achieved Clobex lotion/spray may be used up to 4 weeks for psoriasis per labelling |
| Severe eczema / Atopic dermatitis flare — short-term rescue | Thin film BID to affected areas | Thin film BID; taper or step down within 2 weeks | 50 g/week; max 2 weeks | Not for maintenance; switch to mid-potency steroid or calcineurin inhibitor after flare control Avoid face, groin, axillae |
| Scalp psoriasis or severe scalp dermatoses | Solution or shampoo: apply to dry scalp BID (solution) or daily (shampoo) | Same frequency; 15 min contact for shampoo | 50 mL/week; max 2–4 weeks | Shampoo: apply to dry scalp, lather after 15 min, rinse Clobex shampoo HPA suppression: 5/12 adolescents at 4 weeks |
| Vulvar lichen sclerosus — induction (off-label) | Ointment: fingertip unit once daily at bedtime | Once daily for 4–12 weeks, then taper | Per clinical response | Taper to 2–3 times/week for maintenance; long-term use accepted under specialist supervision Off-label but guideline-supported as first-line by BAD, ISSVD |
| Localized alopecia areata (off-label) | Thin film BID to affected scalp patches | BID for up to 12 weeks | Limited to patches; not for total scalp | Under occlusion (e.g., shower cap overnight) may increase efficacy but also increases HPA risk Monitor for scalp atrophy and telangiectasia |
For chronic conditions requiring intermittent super-potent steroid use, some dermatologists employ a “weekend pulse” or “proactive” approach: after achieving initial control with daily clobetasol propionate (max 2 weeks), the patient transitions to applying clobetasol propionate only on 2 consecutive days per week (e.g., Saturday and Sunday) to previously affected areas. This approach reduces cumulative exposure and HPA axis risk while preventing flares. On the remaining days, a lower-potency steroid or emollient is used. This strategy has the strongest evidence base in psoriasis and lichen sclerosus maintenance.
Pharmacology
Mechanism of Action
Clobetasol propionate is a synthetic fluorinated corticosteroid and a prednisolone analog with exceptionally high glucocorticoid receptor affinity and minimal mineralocorticoid activity. Like all topical corticosteroids, it exerts its effects by binding to intracellular glucocorticoid receptors, forming a receptor-ligand complex that translocates to the nucleus and modulates gene transcription. This produces a broad spectrum of anti-inflammatory, immunosuppressive, antiproliferative, and vasoconstrictive effects in the skin.
Specifically, clobetasol propionate inhibits the release of arachidonic acid from cell membranes by inducing lipocortin (annexin A1), which inhibits phospholipase A2. This reduces the production of prostaglandins, leukotrienes, and other inflammatory mediators. It suppresses the transcription of pro-inflammatory cytokines (including IL-1, IL-6, TNF-alpha) by inhibiting NF-kappa B signaling. It reduces mast cell density and eosinophil activation, decreases capillary permeability (producing vasoconstriction and reduced edema), and inhibits keratinocyte proliferation. The combined anti-inflammatory, immunosuppressive, and antimitotic effects make it highly effective for recalcitrant inflammatory dermatoses, but also underlie its potential for skin atrophy and systemic side effects when used excessively.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Percutaneous; minimal from intact skin. Mean peak plasma ~0.63 ng/mL (healthy skin, 0.05% ointment); ~2.3–4.6 ng/mL (psoriasis/eczema). Increased by inflammation, broken barrier, occlusion, and larger treatment area. | Diseased skin absorbs significantly more drug, increasing systemic risk. Limiting BSA and duration is critical. HPA suppression documented at doses as low as 2 g/day. |
| Distribution | Bound to plasma proteins in varying degrees (as with systemic corticosteroids). Concentrates in the epidermis and dermis at the application site. | Local concentration drives therapeutic effect; systemic distribution is undesirable and dose-limiting. |
| Metabolism | Once absorbed, follows systemic corticosteroid metabolic pathways; metabolized primarily in the liver. Specific metabolic pathways for clobetasol propionate have not been fully characterized. | Hepatic impairment could theoretically slow clearance of absorbed drug, but this is not clinically relevant at standard topical doses. |
| Elimination | Excreted by kidneys (urine) and in bile. Absorbed drug is cleared through standard corticosteroid elimination pathways. | No dose adjustment needed for renal or hepatic impairment when used topically within labeled parameters. |
Side Effects
Adverse effects with clobetasol propionate are predominantly local and relate to its potency. Systemic effects are possible with excessive use. Rates below are from the FDA-approved prescribing information for the emollient cream 0.05% and lotion 0.05% clinical trials.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| HPA axis suppression (with extended use or large BSA) | 25% (1 week, ≥30% BSA); up to 80% (4 weeks lotion) | Dose-, duration-, area-, and occlusion-dependent; generally reversible on discontinuation; most potent predictor of systemic risk |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Burning / Stinging at application site | ~5% | Most common reported adverse reaction in clinical trials; transient; usually self-limiting |
| Pruritus | <2% | Paradoxical in some patients; may indicate developing sensitization |
| Erythema at application site | <2% | Distinct from the treated condition; may indicate irritant or allergic contact dermatitis to the vehicle |
| Skin atrophy | <2% (short courses); higher with prolonged use | Thinning of the epidermis and dermis; can become irreversible with extended use; particularly problematic on the face and flexures |
| Telangiectasia | <2% | Dilated superficial blood vessels; may be irreversible; risk increases with duration and use on the face |
| Folliculitis / Acneiform eruptions | <2% | Steroid folliculitis; more likely under occlusion or on trunk |
| Cracking and fissuring of the skin | <2% | Especially on fingers, palms, and soles with excessive use |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Cushing’s syndrome (iatrogenic) | Rare (reported in infants and adults) | Weeks to months of overuse | Discontinue clobetasol; endocrinology referral; gradual taper to avoid adrenal crisis; may require systemic steroid replacement |
| Adrenal crisis (on abrupt withdrawal after prolonged use) | Rare | Within days of abrupt discontinuation | Emergency systemic corticosteroid replacement; never abruptly stop after prolonged use on large areas |
| Glaucoma / Increased intraocular pressure | Rare; risk with periocular use | Weeks to months | Avoid application near eyes; ophthalmology referral if visual symptoms develop; measure IOP |
| Posterior subcapsular cataracts | Rare; with prolonged periocular use | Months of use near eyes | Ophthalmology referral; avoid periocular application |
| Irreversible skin atrophy and striae | Uncommon with short courses; risk increases with duration | Weeks to months of continuous use | Discontinue use; striae are permanent; counsel patient that atrophy may partially recover over months |
| Allergic contact dermatitis (to vehicle or clobetasol itself) | Rare | Days to weeks | Suspect if condition worsens despite treatment; patch testing; switch vehicle or class |
Abrupt discontinuation of clobetasol propionate after extended use (beyond 2 weeks or on large body surface areas) can precipitate rebound flaring of the underlying condition, and in severe cases, symptoms of adrenal insufficiency. The recommended approach is a gradual step-down: (1) reduce frequency from twice daily to once daily for 1 week; (2) alternate with a mid-potency steroid (e.g., triamcinolone 0.1%) for another 1–2 weeks; (3) transition to maintenance with a low-potency steroid or non-steroidal agent (tacrolimus, pimecrolimus). In psoriasis, abrupt cessation of potent topical steroids has been associated with pustular flares.
Drug Interactions
Clobetasol propionate has minimal systemic absorption under normal use conditions, making pharmacokinetic drug interactions unlikely. The clinically relevant interactions are pharmacodynamic, primarily related to additive immunosuppressive or skin-thinning effects.
Monitoring
Routine laboratory monitoring is not required for short courses (≤2 weeks) on limited body surface area. However, when clobetasol propionate is used on larger areas, for longer durations, or in vulnerable populations, HPA axis evaluation should be considered.
- HPA Axis FunctionIf use exceeds 2 weeks or >20% BSA
Trigger-BasedACTH stimulation test (cosyntropin test), morning plasma cortisol, or urinary free cortisol. Clobetasol has been shown to suppress the HPA axis at doses as low as 2 g/day. In clinical studies, 25% of patients with ≥30% BSA involvement developed adrenal suppression after just 1 week. Recovery is generally prompt upon discontinuation. - Skin Integrity AssessmentEvery visit during treatment
RoutineInspect for signs of skin atrophy (thinning, visible blood vessels, shiny appearance), striae, telangiectasia, and steroid rosacea. These may develop within weeks of use, particularly on the face and flexural areas. Some changes (striae, telangiectasia) may be irreversible. - Treatment DurationEvery visit
RoutineConfirm the patient is not exceeding 2 consecutive weeks of use (4 weeks for specific psoriasis formulations). Verify total weekly application does not exceed 50 g. Patients frequently self-extend potent steroid use beyond the prescribed duration. - Growth Velocity (pediatric)If used in adolescents 12–17 years
Trigger-BasedChildren are more susceptible to systemic absorption due to higher body surface area to body mass ratio. Monitor height velocity if clobetasol use is prolonged or recurrent. Use is not recommended under age 12. - Ocular SymptomsEvery visit if applied to face or near eyes
Trigger-BasedAsk about visual changes, pain, or blurred vision. Topical corticosteroid use near the eyes carries risk of glaucoma, increased IOP, and posterior subcapsular cataracts. Refer to ophthalmology if symptoms occur. - Signs of Secondary InfectionEvery visit
RoutineCorticosteroids suppress local immune defenses. Monitor for signs of bacterial, fungal, or viral superinfection (e.g., worsening despite treatment, impetiginization, tinea incognito, herpes simplex flare). Treat infection before continuing clobetasol.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to clobetasol propionate, other corticosteroids, or any component of the formulation.
- Primary skin infections — Untreated bacterial, viral (including herpes simplex, varicella), or fungal infections of the skin. Corticosteroids mask infection and promote spread.
Relative Contraindications (Specialist Input Recommended)
- Rosacea and perioral dermatitis — Clobetasol propionate should not be used to treat these conditions; it causes exacerbation and dependence.
- Application to the face, groin, or axillae — The labelling explicitly states these areas should be avoided due to enhanced absorption and risk of atrophy and striae. If required in these areas, use the lowest potency for the shortest time.
- Pregnancy — Clobetasol propionate is teratogenic in animals (cleft palate, skeletal abnormalities in mice at subcutaneous doses as low as 0.03 mg/kg). No adequate human data. Use only if the potential benefit justifies the potential risk to the fetus.
Use with Caution
- Pediatric patients <12 years — Not recommended due to higher systemic absorption risk from greater BSA-to-mass ratio. Children have developed HPA axis suppression, Cushing’s syndrome, and growth retardation from topical clobetasol.
- Occlusive dressings — Substantially increase percutaneous absorption; should not be used unless specifically directed by the prescriber for recalcitrant disease, with close monitoring.
- Pre-existing skin atrophy — The Clobex spray and lotion labelling specifically state: do not use if atrophy is present at the treatment site.
- Lactation — Unknown whether clobetasol propionate is excreted in breast milk. Use on the smallest area for the shortest duration; avoid application to the breast.
- Patients planning surgery — Inform the surgical team if using clobetasol propionate, as HPA axis suppression may affect the stress response to surgery.
Clobetasol propionate is a super-high potency topical corticosteroid that has been shown to suppress the HPA axis at doses as low as 2 g per day. Patients receiving super-potent corticosteroids should not be treated for more than 2 consecutive weeks at a time, and only small areas should be treated at any one time, due to the increased risk of HPA axis suppression. Cushing’s syndrome has been reported in both infants and adults following prolonged use. If HPA axis suppression is noted, the drug should be withdrawn gradually, the frequency of application reduced, or a less potent corticosteroid substituted. Recovery of HPA axis function is generally prompt upon discontinuation.
Patient Counselling
Purpose of Therapy
Clobetasol propionate is a very strong prescription steroid cream/ointment used to reduce redness, itching, swelling, and discomfort caused by skin conditions that have not responded to milder treatments. It is intended for short-term use only — typically no more than 2 weeks — and should not be used as a long-term moisturizer or maintenance therapy.
How to Take
Apply a thin layer to the affected skin area only, twice a day, and rub in gently. Do not apply to healthy skin, and do not use more than prescribed. Wash your hands after applying, unless the hands are the area being treated. Do not cover the treated area with bandages or tight dressings unless directed by your prescriber.
Sources
- Clobetasol Propionate Cream, 0.05% (Emollient) — Full Prescribing Information. Sun Pharmaceutical Industries. DailyMedSource for emollient cream adverse reaction rates (burning/stinging 5%, pruritus/erythema/atrophy <2%), HPA suppression data (25% at 1 week with ≥30% BSA), and 50 g/week dosage limit.
- Clobex (clobetasol propionate) Lotion, 0.05% — Full Prescribing Information. Galderma Laboratories. FDA Label (2012)Source for lotion-specific HPA suppression data (9/14 patients suppressed at 2 weeks; 8/10 at 4 weeks in psoriasis), clinical trial efficacy, and atopic dermatitis indication data.
- Clobex (clobetasol propionate) Spray, 0.05% — Full Prescribing Information. Galderma Laboratories. FDA Label (2018)Source for spray formulation dosing in psoriasis (≤20% BSA), pregnancy/lactation data, and teratogenicity findings (umbilical hernia in rats at >12.5 mcg/kg/day SC).
- Clobetasol Propionate Ointment, 0.05% — Full Prescribing Information. DailyMedSource for ointment-specific HPA axis suppression threshold (2 g/day), teratogenicity data (mice: cleft palate at 0.03 mg/kg SC; rabbits: 3–10 mcg/kg SC), and occlusive dressing warnings.
- Feldman SR. Relative potency of various topical corticosteroids. UpToDate. UpToDateComprehensive classification of topical corticosteroids by potency; positions clobetasol propionate as US Class I (super-high potency).
- Torsekar RG, Koranne RV. Topical corticosteroid use and misuse: a clinical review. Indian J Dermatol. 2023;68(5):480-490.Review addressing duration limits, step-down strategies, and consequences of topical corticosteroid misuse including rebound flares and steroid-dependent dermatitis.
- Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;(12):CD008240. DOI: 10.1002/14651858.CD008240.pub2Cochrane review establishing clobetasol propionate 0.05% ointment as first-line therapy for vulvar lichen sclerosus with high-quality evidence.
- British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178(4):839-853. DOI: 10.1111/bjd.16241BAD guideline recommending clobetasol propionate 0.05% as first-line for vulvar lichen sclerosus with specific tapering protocols for long-term maintenance.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. DOI: 10.1016/j.jaad.2014.03.023AAD guideline on topical corticosteroid use in atopic dermatitis, including potency selection, duration limitations, and step-down strategies.
- Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406-420. DOI: 10.1111/j.0906-6705.2006.00435.xDetailed review of the mechanisms underlying corticosteroid-induced skin atrophy, including collagen degradation and dermal thinning relevant to clobetasol’s adverse effect profile.
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. DOI: 10.1016/j.jaad.2005.01.010Comprehensive review of local and systemic adverse effects of topical corticosteroids, including HPA suppression thresholds, skin atrophy mechanisms, and ocular complications.
- Duong TV, et al. Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis. Br J Clin Pharmacol. 2025. DOI: 10.1002/bcp.70102PBPK modelling study demonstrating that systemic clobetasol exposure increases with impaired skin barrier and larger application area; supports 50 g/week max and ≤30% BSA recommendation.
- Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093-1105. PubMed: 20027937Practical review of topical corticosteroid pharmacology, vehicle selection, and prescribing strategies including pulse and weekend protocols for super-potent steroids.